NERV - Minerva Neurosciences, Inc.

1.79
0.030   1.676%

Share volume: 352
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$1.76
0.03
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
14%
Profitability 0%
Dept financing 11%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.29%
1 Month
5.29%
3 Months
-28.69%
6 Months
-29.65%
1 Year
-25.73%
2 Year
-52.39%
Key data
Stock price
$1.79
P/E Ratio 
10.80
DAY RANGE
$1.79 - $1.79
EPS 
$0.19
52 WEEK RANGE
$1.15 - $3.69
52 WEEK CHANGE
-$24.15
MARKET CAP 
15.537 M
YIELD 
N/A
SHARES OUTSTANDING 
6.993 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-30-2025
BETA 
-0.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$8,370
AVERAGE 30 VOLUME 
$18,273
Company detail
CEO: Rémy H. Luthringer
Region: US
Website: minervaneurosciences.com
Employees: 9
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Minerva Neurosciences, Inc. focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for schizophrenia; MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.

Recent news
loading